CD274 and neoplasm: Similarly, IHC (Immunohistochemistry) quantified PD-L1 (CD274) expression, microsatellite instability, and Tumor Mutation Burden (TMB) have been used in clinical settings to assess whether NSCLC patients could benefit from Immune Checkpoint Inhibitor (ICIs) (Table S1A).